Houssami N, Ciatto S, Martinelli F, Bonardi R, Duffy S W
Istituto per lo Studio e la Prevenzione Oncologica, Istituto Scientifico della Regione Toscana, Florence, Italy; Screening and Test Evaluation Program, School of Public Health, University of Sydney, Sydney, Australia.
Istituto per lo Studio e la Prevenzione Oncologica, Istituto Scientifico della Regione Toscana, Florence, Italy.
Ann Oncol. 2009 Sep;20(9):1505-1510. doi: 10.1093/annonc/mdp037. Epub 2009 Mar 17.
The impact of early detection of second breast cancers in women who have survived a primary breast cancer is unknown. We examined the prognostic effect of detection of ipsilateral breast relapse (IBR) or contralateral breast cancer (CBC) in the asymptomatic relative to symptomatic phase.
Subjects were women with histology-verified second (invasive or in situ) breast cancer (N = 1044) in a breast centre in Florence (1980-2005). Symptom status, test, tumour stage, and outcomes data were obtained from clinical records and linkage with mortality registry. Disease-specific survival was measured from first cancer diagnosis to avoid lead-time bias. Sensitivity analysis was used to allow for length-time bias.
Second cancers (IBR = 455; CBC = 589; median age 60 years) were diagnosed in 699 asymptomatic and 345 symptomatic women (67% versus 3%, P < 0.0001). Mammography was more sensitive than clinical examination (86% versus 57%, P < 0.0001); however, 13.8% of cases were only identified clinically. Asymptomatic cancers were smaller than symptomatic for both IBR (P < 0.001) and CBC (P < 0.001). Early-stage tumours were more frequent in asymptomatic (58.1%) than symptomatic (22.6%) women (P < 0.0001). Fewer women with asymptomatic than symptomatic CBC had node metastases (P = 0.0001). Hazard ratio (HR) for asymptomatic (relative to symptomatic) detection was 0.51 (0.32-0.80) for IBR, 0.53 (0.36-0.78) for CBC, and 0.53 (0.40-0.72) in all subjects (P < 0.0001). Length bias-adjusted HRs ranged from 0.53 to 0.73.
Detection of second breast cancers in the asymptomatic phase leads to detection of early-stage cancer and improves relative survival by between 27% and 47%.
原发性乳腺癌存活女性中早期发现第二原发性乳腺癌的影响尚不清楚。我们研究了在无症状期与有症状期检测同侧乳腺复发(IBR)或对侧乳腺癌(CBC)的预后效果。
研究对象为佛罗伦萨一家乳腺中心组织学确诊为第二原发性(浸润性或原位)乳腺癌的女性(N = 1044)(1980 - 2005年)。症状状态、检查、肿瘤分期及转归数据来自临床记录并与死亡登记处进行关联。从首次癌症诊断开始测量疾病特异性生存,以避免提前期偏倚。采用敏感性分析以考虑病程长短偏倚。
699例无症状女性和345例有症状女性被诊断为第二原发性癌症(IBR = 455例;CBC = 589例;中位年龄60岁)(67%对3%,P < 0.0001)。乳腺钼靶检查比临床检查更敏感(86%对57%,P < 0.0001);然而,13.8%的病例仅通过临床检查发现。无症状癌症在IBR(P < 0.001)和CBC(P < 0.001)中均比有症状癌症更小。早期肿瘤在无症状女性(58.1%)中比有症状女性(22.6%)中更常见(P < 0.0001)。无症状CBC患者发生淋巴结转移的人数少于有症状CBC患者(P = 0.0001)。无症状(相对于有症状)检测的风险比(HR)对于IBR为0.51(0.32 - 0.80),对于CBC为0.53(0.36 - 0.78),在所有受试者中为0.53(0.40 - 0.72)(P < 0.0001)。病程长短偏倚调整后的HR范围为0.53至0.73。
在无症状期检测第二原发性乳腺癌可发现早期癌症,并使相对生存率提高27%至47%。